4th GPCRs-Targeted Drug Discovery Summit

Transforming the Discovery of Novel GPCR-Targeted Therapies

With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs, from small molecules to therapeutic proteins and antibodies.

The 4th GPCRs-Targeted Drug Discovery Summit returned to Boston to showcase the hottest targets of interest, mechanism of action of new GPCR ligands, cutting-edge computational tools to identify high-potential candidates, and effective translational strategies to drive forward discovery & development pipelines to patients in need.